About the Campaign

The breakthrough direct-acting antivirals (DAAs) can cure over 90% of people with chronic hepatitis C, and generic versions show similar safety and efficacy rates as brand drugs. Generic competition to accelerate the number of people who start treatment is stalled due to Gilead’s, AbbVie’s, and their sub-licensees’ delay or failure to register their drugs, blocking access to the cure in countries with some of the highest rates of hepatitis C. The ongoing, global campaign works to accelerate equitable access to affordable, generic hepatitis C treatments.